A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A phase 1/2 trial of A2B395 in colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma and triple-negative breast cancer, run by A2 Biotherapeutics Inc., now recruiting.
Overview
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT06682793 by A2 Biotherapeutics Inc., with 240 participants planned, started 2025-05-22 and due to reach its primary completion in 2029-03-31. Interventions recorded: A2B395.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma, Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Colorectal cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Renal cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.